Study of Efficacy and Safety of Inclisiran in Asian Participants With Atherosclerotic Cardiovascular Disease (ASCVD) or ASCVD High Risk and Elevated Low Density Lipoprotein Cholesterol (LDL-C)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 345 participants.

Also called NCT04765657

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 345 participants (enrolled count) (from the registry)
Sponsor
  • Novartis Registry lists this organization as the lead sponsor
Registry
  • NCT NCT04765657
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China, Singapore, South Korea, Taiwan (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT04765657. Randomized; quadruple masking; primary purpose treatment. Start 2021-03-01 (actual); primary completion 2022-06-09 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Study of Efficacy and Safety of Inclisiran in Asian Participants With Atherosclerotic Cardiovascular Disease (ASCVD) or ASCVD High Risk and Elevated Low Density Lipoprotein Cholesterol (LDL-C)
Condition
Hypercholesterolemia
Intervention (Drug)
inclisiran sodium
Intervention (Drug)
Placebo
Lead sponsor
Novartis Pharmaceuticals (class: industry)

Record details

Record id
cardio:ct-nct04765657
Content hash
cc522d91050e13ed4ecf8bd3976a4b05859b2ce2797e47bfb53d329295b4c217